CTOs on the Move


 
  • Number of Employees:
  • Annual Revenue:

  • ,

Executives

Name Title Contact Details

Similar Companies

AI REV

AI REV is a boutique AI consulting company with partners having extensive practical AI experience and strong track records. We provide state-of-the-art consulting & AI project delivery for enterprise clients. AI REVs goal is to reduce the average human workweek from 40 hours to 20. We are working towards achieving this by augmenting companies with AI-powered efficiency improvements. Our solutions have saved our customers up to 25% on related departamental costs, substantially decreased their operational risk, and enabled the reallocation of manpower to more pressing issues. We offer end-to-end Machine Learning, Data Science, AI & software development, Strategic Consulting, and Engineering Workshops.

CFOstartup

Somos una empresa internacional especializada en startups y empresas tech de LATAM. Acompañamos el crecimiento acelerado de los founders garantizándoles en cada etapa el cumplimiento de todos sus compromisos financieros, contables, impositivos y legales en cada país en el que operan. Nuestras soluciones contemplan servicios de compliance, impuestos internacionales, softlanding, CFO Services, transaction services y legal services. Nos caracterizamos por nuestra velocidad de respuesta, profesionalismo y calidad en la ejecución.

Cogency Global Inc.

Cogency Global Inc. is a New York-based company that provides registered agent, process agent, corporate compliance, and transactional legal support services. Founded in 1980, it serves clients worldwide across various industries, including nonprofits. The company employs around 300 people and generates approximately $63 million in annual revenue. With expertise in over 4,000 jurisdictions, Cogency offers localized services and maintains a multilingual team for 24-hour support. The company provides a wide range of services tailored for law firms, nonprofits, lenders, and businesses. These include registered and process agent services, corporate compliance and filings, and transactional support. Cogency also offers international solutions with country-specific expertise to ensure smooth operations. Its technology-enabled tools enhance service delivery, featuring data-driven reporting and online platforms for document organization and compliance tracking.

Lang Specialty Trailers

We manufacture portable restroom trailers and shower trailers that are durable, elegant, and easy to use for the professional restroom operator. From luxury restroom trailers to pre-owned trailers, Lang Specialty Trailers has you covered. Our goal is to create innovative restroom trailers that are not only eye appealing, but are durable, easy to install, easy to clean, and functional for the professional restroom operator.

IMUNON

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.